Psoriatic Arthritis

FDA approves PDE-4 inhibitor for treating psoriatic arthritis

Publish date: March 21, 2014

Publish date: February 26, 2014

Publish date: February 5, 2014

Publish date: November 14, 2013

Major finding: After 16 weeks of treatment, the investigational drug apremilast achieved an ACR20 response of 29.2% at 20 mg twice daily as first-...

Publish date: November 4, 2013

Major finding: At 48 weeks, a higher proportion of psoriatic arthritis patients in the intensive management group achieved ACR70, compared with...

Publish date: September 23, 2013

Publish date: June 25, 2013

Major finding: ACR 20 response at 1 year was 57%-63% for patients given apremilast.Data source: PALACE 1, a 504-patient, phase III, multicenter,...